TuisPTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Vorige sluiting
$0,095
Jaarwisseling
$0,087 - $0,11
Markkapitalisasie
68,91 bn IDR
Gemiddelde volume
62,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
IDX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(IDR) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 7,91 bn | 7,16% |
Bedryfskoste | 2,29 bn | 15,55% |
Netto inkomste | 573,28 mjd | 6,97% |
Netto winsgrens | 7,25 | -0,14% |
Wins per aandeel | 12,41 | 7,73% |
EBITDA | 874,81 mjd | 1,14% |
Effektiewe belastingkoers | 23,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(IDR) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 4,32 bn | 45,45% |
Totale bates | 28,75 bn | 5,78% |
Totale aanspreeklikheid | 4,84 bn | 0,67% |
Totale ekwiteit | 23,91 bn | — |
Uitstaande aandele | 46,15 mjd | — |
Prys om te bespreek | 0,00 | — |
Opbrengs op bates | 6,15% | — |
Opbrengs op kapitaal | 7,16% | — |
Kontantvloei
Netto kontantverandering
(IDR) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 573,28 mjd | 6,97% |
Kontant van bedrywe | 1,16 bn | 22,56% |
Kontant van beleggings | -176,64 mjd | 33,78% |
Kontant van finansiering | -421,11 mjd | 51,91% |
Netto kontantverandering | 481,86 mjd | 1 978,42% |
Beskikbare kontantvloei | 752,00 mjd | 13,84% |
Meer oor
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Gestig
10 Sep. 1966
Webwerf
Werknemers
12 924